Top Line: Is 60 Gy in 8 fractions a safe option for patients with central NSCLC?
The Study: EORTC 22113-08113 (LungTech) was a single-arm phase 2 trial that evaluated an 8-fraction regimen for patients with central NSCLC. In the trial, central tumors were defined as those within 2cm or abutting the proximal bronchial tree, or tumors adjacent to the mediastinal or pericardial pleura. Tumors up to 7 cm in size were allowed. Importantly, this criteria did not differentiate between central and ultra-central. 60 Gy in 8 fractions was prescribed to the PTV such that 95% received the prescribed dose with a maximum dose of at least 110% and up to 130%. The goal maximum dose for the PBT was a D0.05cc of 44 Gy. However, when the tumor abutted the main bronchus, up to 0.5cc could receive 60 Gy as long as the contralateral wall was limited to a D0.05cc of 44 Gy. When this couldn’t be achieved, the prescription was reduced to 56 Gy or it could be undercovered as long as 95% received 80% of the prescribed dose. The trial was small with just 31 patients treated. Most had squamous cell carcinoma (48.4%), and the median tumor size was 2.6cm. In retrospect, 19.4% had ultracentral tumors that were within 1cm of the mainstem bronchus or trachea. At 3 years, freedom from local progression was 81.5%. The rates of regional and distant progression were 3.3% and 29.8%. The rate of acute grade 3+ toxicity was 16.1%, which included one (3.2%) acute grade 5 event. The rate of late grade 3+ events related to SBRT was 19.4%, which included one (3.2%) grade 5 hemoptysis event in a patient who had a bronchoscopic biopsy near the treatment site. Thus, the outcomes of LungTech are comparable to those of the central RTOG 0813 trial and safer than those of the ultracentral HILUS trial.
TBL: In the LungTech trial, 60 Gy in 8 fractions, with care taken to respect bronchial dose constraints, resulted in good local control and acceptable toxicity in patients with central (80%) and ultracentral (20%) NSCLC. | Levy, J Thorac Oncol 2024
The Study: EORTC 22113-08113 (LungTech) was a single-arm phase 2 trial that evaluated an 8-fraction regimen for patients with central NSCLC. In the trial, central tumors were defined as those within 2cm or abutting the proximal bronchial tree, or tumors adjacent to the mediastinal or pericardial pleura. Tumors up to 7 cm in size were allowed. Importantly, this criteria did not differentiate between central and ultra-central. 60 Gy in 8 fractions was prescribed to the PTV such that 95% received the prescribed dose with a maximum dose of at least 110% and up to 130%. The goal maximum dose for the PBT was a D0.05cc of 44 Gy. However, when the tumor abutted the main bronchus, up to 0.5cc could receive 60 Gy as long as the contralateral wall was limited to a D0.05cc of 44 Gy. When this couldn’t be achieved, the prescription was reduced to 56 Gy or it could be undercovered as long as 95% received 80% of the prescribed dose. The trial was small with just 31 patients treated. Most had squamous cell carcinoma (48.4%), and the median tumor size was 2.6cm. In retrospect, 19.4% had ultracentral tumors that were within 1cm of the mainstem bronchus or trachea. At 3 years, freedom from local progression was 81.5%. The rates of regional and distant progression were 3.3% and 29.8%. The rate of acute grade 3+ toxicity was 16.1%, which included one (3.2%) acute grade 5 event. The rate of late grade 3+ events related to SBRT was 19.4%, which included one (3.2%) grade 5 hemoptysis event in a patient who had a bronchoscopic biopsy near the treatment site. Thus, the outcomes of LungTech are comparable to those of the central RTOG 0813 trial and safer than those of the ultracentral HILUS trial.
TBL: In the LungTech trial, 60 Gy in 8 fractions, with care taken to respect bronchial dose constraints, resulted in good local control and acceptable toxicity in patients with central (80%) and ultracentral (20%) NSCLC. | Levy, J Thorac Oncol 2024

